| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3282819 | Clinical Gastroenterology and Hepatology | 2013 | 13 Pages |
Abstract
A testing-based strategy is a cost-effective alternative to the current strategy of empiric dose escalation for managing patients with Crohn's disease who have lost responsiveness to infliximab. The basis for this difference is lower cost at similar outcomes.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Fernando S. Velayos, James G. Kahn, William J. Sandborn, Brian G. Feagan,